A cute respiratory distress syndrome (ARDS) is a common cause of respiratory failure and death that is characterized by severe and persistent inflammation in the lung as well as systemic inflammation (1) . Mechanical ventilation with lung protective strategies decreases inflammation and improves survival (2, 3) , but additional approaches are needed for optimal modification of the inflammatory process in ARDS. To that end, the potential utility of corticosteroids (CS) has been an active and controversial area of research for several decades. Early studies employing high-dose CS demonstrated no significant benefit and possible harm (4, 5) , whereas more recent controlled trials using prolonged, lower dose CS have yielded variable results on mortality and secondary outcomes (6, 7) . Although some meta-analyses suggest an improvement in ARDS mortality and ventilator-free days with prolonged low-dose therapy (8, 9) , not all recent data have been positive. A cohort analysis of 208 patients with ARDS secondary to influenza A/H1N1 infection revealed that those treated with CS had higher rates of death, secondary infection, and ventilator duration (10) . Given the heterogeneous nature of ARDS and the pleiotropic effects of CS, it is not surprising that variable results have been observed in clinical trials. Thus, the optimal timing, duration, dose, and discontinuation strategy of CS, as well as the appropriate selection of patients most likely to benefit, all remain incompletely defined.
In this issue of Critical Care Medicine, Karnatovskaia et al (11) address another aspect of clinical uncertainty pertaining to this topic: does prior CS use by those at risk for ARDS alter the clinical course? Several preventative trials in the 1980s employed high-dose steroids in already hospitalized patients in an attempt to prevent or ameliorate ARDS (5, 12, 13) . A meta-analysis of these trials suggests increased risk of ARDS development and death in the CS-treated patients (8) . In an observational cohort study of 688 ICU patients from a single center, prior CS use in a small subset of these patients did not alter risk for development of ARDS on multivariate analysis but was a significant predictor for increased mortality in those who did develop ARDS (14) . However, no definitive trial exists concerning the effects of prior CS use on ARDS risk and outcomes, and with the paucity of data in this area, equipoise remains.
The current study by Karnatovskaia et al (11) investigates these questions through a preplanned retrospective subgroup analysis of a prospectively identified cohort collected to determine the frequency and outcome of ARDS development in atrisk patients and to validate the Lung Injury Prediction Score (15) . The original study enrolled 5,584 hospitalized patients with risk factors for ARDS. Of these, 495 receiving inhaled CS at the time of enrollment (either alone or concomitantly with systemic CS) were excluded from further analysis, leaving 364 on systemic CS alone for comparison with 4,725 patients not receiving any CS (11) . The authors hypothesized that prehospital CS therapy would have a protective effect on ARDS risk and outcomes given the beneficial effects of CS treatment in some previous trials (8, 9) . However, the prevalence of ARDS was not different between those receiving prehospital systemic CS and those who did not (7.7% and 6.9%, respectively) (11). To strengthen their analysis, the authors then performed propensity scoring to identify a subset of patients most closely matched for all available covariates except for CS therapy. Three hundred fifty-four patients who received prehospital systemic CS were matched to 1,093 who did not. After this adjustment, there were no significant differences in the risk of ARDS, invasive ventilation, or in-hospital mortality between the two groups. The authors conclude that prior systemic CS use did not affect the risk for ARDS or its clinical course after development of the syndrome.
Interpretation of the clinical relevance of this study must begin with a review of its limitations. Although the subgroup analysis was preplanned and involved a prospectively identified cohort, it does not rise to the level of evidence provided by a prospective, randomized, blinded, and controlled trial. The propensity score matching strengthens the analysis but cannot control for all potential confounders. Another significant limitation is that the data collected do not provide any details concerning the specific medication, dose, or duration of systemic CS therapy being taken by patients prior to hospitalization. Patients were categorized as receiving CS based on a review of the medical record at hospital admission. Prehospital compliance with the prescribed medication was also not determined. As a result, there likely existed a great deal of therapeutic heterogeneity within the systemic CS group, which serves to weaken the conclusions that can be drawn from these results. For example, is there any association between systemic CS dose and ARDS risk? Is there a difference in ARDS risk between patients chronically using CS and those receiving a brief steroid taper? Does the use of inhaled CS (these patients were excluded from analysis) affect ARDS prevalence or outcomes? These questions cannot be answered by the current study.
Despite these limitations, Karnatovskaia et al (11) have advanced the debate about the role of CS in ARDS by providing the first study specifically focused on the effects of prehospital CS on ARDS risk and outcomes. Their data suggest that outpatient CS therapy does not alter the natural clinical course in patients at risk for the development of ARDS. However, given the multiple beneficial effects of CS on ARDS pathophysiology and the positive results in some clinical trials of low-dose CS early in ARDS, there remains some uncertainty about the potential use of CS as a prophylactic agent in highrisk patients. The recently announced National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network is one potential avenue for providing the randomized control trial needed to determine which at-risk patients, if any, may benefit from CS therapy. Until such data are available, the debate is likely to continue.
